GleamWall
中文EN

BTCY BIOTRICITY INC.

Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1630113 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY11.7%
TTM net income YoY38.0%
TTM EPS YoY-4.9%
Revenue 3-yr CAGR14.9%
Net income 3-yr CAGR—

Margins

Gross margin81.8%
Operating margin9.7%
Net margin-16.7%
FCF margin—
EBITDA margin9.7%

Returns

ROE—
ROA-45.2%
ROIC (approx.)—
Asset turnover2.71x

Leverage & solvency

Liabilities / assets662.7%
Debt / equity—
Current ratio0.15x
Interest coverage0.49x

Cash quality & payout

Operating cash flow / net income0.09x
Accruals ratio-41.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q22026-09-302027Q12026-06-302026Q4*2026-03-312026Q32025-12-312026Q22025-09-302026Q12025-06-302025Q4*2025-03-312025Q32024-12-31
Income statement
Revenue$4.33M$4.28M$4.25M$3.99M$3.89M$3.87M$3.70M$3.62M
Cost of revenue$725,733$746,136$851,608$736,343$704,297$757,193$724,416$855,140
Gross profit$3.61M$3.53M$3.40M$3.25M$3.18M$3.12M$2.98M$2.76M
R&D expense$884,501$673,444$841,669$623,567$602,798$696,163$572,567$551,216
SG&A expense$2.39M$2.70M$1.86M$2.19M$2.30M$2.14M$3.26M$2.38M
Operating income$338,715$158,068$694,557$440,915$273,819$281,945-$855,466-$168,982
Interest expense$854,081$851,753$840,938$810,339$860,419$850,254$891,752$849,538
Pretax income-$808,161-$959,468-$324,182-$717,067-$690,913-$671,977-$1.94M-$1.23M
Net income-$808,161-$959,468-$324,182-$717,067-$690,913-$671,977-$1.94M-$1.23M
EBITDA$340,204$159,556$696,045$442,403$275,308$283,433-$853,978-$167,493
EPS (basic)-0.05-0.05—-0.04-0.03-0.03—-0.05
EPS (diluted)-0.05-0.05—-0.04-0.03-0.03—-0.05
Weighted avg. shares (diluted)20.75M23.10M—27.59M26.77M26.28M—24.23M
Balance sheet
Cash & equivalents$268,998$466,503$149,789$256,357$308,460$391,292$365,145$509,601
Receivables$2.55M$2.40M$2.93M$1.58M$2.10M$1.86M$1.66M$1.24M
Inventory$1.28M$1.43M$1.34M$1.97M$2.26M$1.78M$1.56M$1.57M
Current assets$5.86M$5.60M$5.86M$4.98M$5.54M$5.14M$4.64M$4.86M
PP&E, net$669$2,157$3,646$5,134$6,622$8,111$9,599$11,087
Total assets$6.12M$6.02M$6.45M$5.69M$6.32M$6.04M$5.64M$5.99M
Current liabilities$38.15M$37.34M$37.14M$23.80M$23.61M$21.81M$20.64M$21.14M
Total liabilities$40.55M$39.72M$39.41M$38.21M$37.98M$36.84M$35.66M$35.78M
Shareholders' equity-$35.99M-$35.41M-$34.68M-$34.24M-$33.41M-$32.80M-$32.01M-$31.94M
Shares outstanding21.63M20.07M28.60M27.81M26.79M26.57M26.08M24.39M
Cash flow statement
Operating cash flow$3,521$507,227-$20,905-$740,291$415,630-$373,389-$400,785-$88,093
Financing cash flow-$198,525-$190,935-$91,546$721,325-$507,748$435,705$165,020$424,960
Depreciation & amortization$1,489$1,488$1,488$1,488$1,489$1,488$1,488$1,489
Stock-based compensation$0$339,970$7,695$6,001$6,001$5,935$1.29M$56,939

Free plan shows the latest 8 periods; Pro shows all 53 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.